奥妥珠单抗治疗自身免疫性疾病研究进展  

Advances in the treatment of autoimmune diseases with obinutuzumab

作　　者：李路瑶 王莎 杨向东[1] LI Luyao;WANG Sha;YANG Xiangdong(Department of Nephrology,Qilu Hospital of Shandong University,Ji'nan 250012,Shandong Province,China)

机构地区：[1]山东大学齐鲁医院肾内科,山东济南250012

出　　处：《世界临床药物》2025年第2期203-206,共4页World Clinical Drug

基　　金：国家自然基金面上项目(82270775);山东大学临床研究项目(2021SDUCRCB007)。

摘　　要：自身免疫性疾病(autoimmune disease,AID)是一类以对自身抗原的炎症反应过度为特征的疾病,B淋巴细胞是AID发病核心,以耗竭B淋巴细胞为目的的抗白细胞分化抗原(cluster of differentiation,CD)20单克隆抗体已被广泛用于AID的治疗。Ⅱ型人源化抗CD20单克隆抗体奥妥珠单抗(obinutuzumab)可显著削减B淋巴细胞数量,抑制自身抗体的产生,可被用于治疗AID。现就奥妥珠单抗在AID中的应用进展作一综述,旨在为临床用药提供参考。Autoimmune disease(AID) is a class of diseases characterized by excessive inflammatory response to autoantigens,B lymphocytes are the core of the pathogenesis of AID,and cluster of differentiation(CD)20 monoclonal antibodies targeting at B lymphocytes depletion are widely used in the treatment of AID.Obinutuzumab,a type Ⅱ humanized anti-CD20 monoclonal antibody,can significantly reduce the number of B lymphocytes and inhibit the production of autoantibodies,and can be used to treat AID.This article reviewed the application progress of obinutuzumab in AID,aiming to provide some reference for clinical use.

关 键 词：奥妥珠单抗 自身免疫性疾病 抗白细胞分化抗原20 

分 类 号：R593.2[医药卫生—内科学]